RCUS
Arcus Biosciences, Inc.Company with tickers: RCUS
CIK
1724521
CUSIP
03969F109
Shares Outstanding
125,773,162
13F Activity (30d)
187 filings
181 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $17,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Revenue (ASC 606) | $7,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $151,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $122,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-134,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-128,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-1.02 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-1.02 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |